Palantir stock jumps +12% on report of new FDA contract

• Palantir Technologies (PLTR, +12%) is rallying in morning trading after it reportedly inks a 3-year contract with the FDA.
• The contract, to power drug review and inspections, is worth $44.4M, Bloomberg says.
• Newly-public Palantir shares have been easing after a strong November, down more than 7% since a high on Nov. 25 including today's gain.
• Seeking Alpha authors lean slightly bullish on the stock, with 11 bullish or very bullish, eight neutral and two bearish.